After Piper Jaffray and Cowen & Co. gave Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE) a Buy rating last month, the company received another Buy, this time from J.P. Morgan. Analyst Cory Kasimov maintained a Buy rating on Ultragenyx Pharmaceutical, Inc. yesterday and set a price target of $75. The company’s shares closed yesterday at $67.25.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 0.6% and a 41.8% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., ACADIA Pharmaceuticals Inc, and Global Blood Therapeutics.
Ultragenyx Pharmaceutical, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $75, representing an 11.5% upside. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock with a $75 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $90.98 and a one-year low of $37.44. Currently, Ultragenyx Pharmaceutical, Inc. has an average volume of 632.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.
